MA50673A - Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih - Google Patents

Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih

Info

Publication number: MA50673A
Authority: MA; Morocco
Prior art keywords: prophylactic; virus infection; hiv virus; therapeutic; useful
Prior art date: 2016-08-19

Application number

MA050673A

Other languages

English (en)

Inventor

Michael Graupe

Steven J Henry

John O Link

Charles William Rowe

Roland D Saito

Scott D Schroeder

Dimitrios Stefanidis

Winston C Tse

Jennifer R Zhang

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-19

Filing date

2017-08-17

Publication date

2020-08-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50673(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-08-17 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2020-08-05 Publication of MA50673A publication Critical patent/MA50673A/fr

Links

230000001225 therapeutic effect Effects 0.000 title 2
150000001875 compounds Chemical class 0.000 title 1
230000000069 prophylactic effect Effects 0.000 title 1
230000009385 viral infection Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

MA050673A 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih MA50673A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662377312P	2016-08-19	2016-08-19
US201762457555P	2017-02-10	2017-02-10

Publications (1)

Publication Number	Publication Date
MA50673A true MA50673A (fr)	2020-08-05

Family

ID=59714166

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA050673A MA50673A (fr)	2016-08-19	2017-08-17	Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih
MA42795A MA42795B1 (fr)	2016-08-19	2017-08-17	Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA42795A MA42795B1 (fr)	2016-08-19	2017-08-17	Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Country Status (40)

Country	Link
US (3)	US10071985B2 (fr)
EP (3)	EP4265299A3 (fr)
JP (4)	JP6716785B2 (fr)
KR (3)	KR102180740B1 (fr)
CN (2)	CN109890808B (fr)
AU (4)	AU2017312102B2 (fr)
BR (2)	BR122020001791B1 (fr)
CA (1)	CA3021227C (fr)
CL (1)	CL2019000415A1 (fr)
CO (1)	CO2019001379A2 (fr)
CR (1)	CR20190084A (fr)
CY (1)	CY1122296T1 (fr)
DK (2)	DK3597646T3 (fr)
DO (1)	DOP2019000033A (fr)
EC (1)	ECSP19011209A (fr)
ES (2)	ES2746374T3 (fr)
FI (1)	FI3597646T3 (fr)
FR (1)	FR22C1063I2 (fr)
HK (1)	HK1256904B (fr)
HR (1)	HRP20231018T1 (fr)
HU (3)	HUE063811T2 (fr)
IL (1)	IL264644B (fr)
JO (1)	JOP20180123A1 (fr)
LT (3)	LT3347352T (fr)
MA (2)	MA50673A (fr)
MX (1)	MX369307B (fr)
MY (1)	MY191466A (fr)
NL (1)	NL301212I2 (fr)
NZ (1)	NZ750706A (fr)
PE (2)	PE20190910A1 (fr)
PH (1)	PH12019500335A1 (fr)
PL (2)	PL3347352T3 (fr)
PT (2)	PT3597646T (fr)
SA (1)	SA519401123B1 (fr)
SG (2)	SG10201912535VA (fr)
SI (2)	SI3347352T1 (fr)
TW (4)	TWI664966B (fr)
UY (1)	UY37367A (fr)
WO (1)	WO2018035359A1 (fr)
ZA (1)	ZA201901430B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2729448E (pt)	2011-07-06	2015-12-02	Gilead Sciences Inc	Compostos para o tratamento de vih
US10202353B2 (en)	2014-02-28	2019-02-12	Gilead Sciences, Inc.	Therapeutic compounds
CN109890808B (zh)	2016-08-19	2020-08-07	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) *	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
JP7083398B2 (ja)	2018-02-15	2022-06-10	ギリアードサイエンシーズ，インコーポレイテッド	ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
CA3175384A1 (fr)	2018-02-16	2019-08-22	Gilead Sciences, Inc.	Methodes et intermediaires pour preparer des composes therapeutiques utiles dans le traitement d'une infection virale des retroviridae
WO2019246545A1 (fr) *	2018-06-21	2019-12-26	Drexel University	Inhibiteurs de protéine capsidique du vih-1 à petites molécules et leurs procédés d'utilisation
KR20210033492A (ko) *	2018-07-16	2021-03-26	길리애드 사이언시즈, 인코포레이티드	Hiv의 치료를 위한 캡시드 억제제
BR112021001617A2 (pt)	2018-08-09	2021-04-27	VIIV Healthcare UK (No.5) Limited	inibidores de replicação do vírus da imunodeficiência humana
WO2020053811A1 (fr)	2018-09-14	2020-03-19	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3853228A1 (fr)	2018-09-20	2021-07-28	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP7398448B2 (ja)	2018-10-24	2023-12-14	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
EP3870576B1 (fr)	2018-10-24	2024-01-24	VIIV Healthcare UK (No.5) Limited	Derives de benzopyrazole en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
ES2942998T3 (es)	2018-10-25	2023-06-08	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de inmunodeficiencia humana
EP3873607B1 (fr)	2018-10-29	2023-11-29	VIIV Healthcare UK (No.5) Limited	Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3876942A1 (fr)	2018-11-05	2021-09-15	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3877387A1 (fr)	2018-11-05	2021-09-15	ViiV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UA128041C2 (uk)	2019-01-25	2024-03-20	Браун Юніверсіті	Спосіб лікування пов'язаного з віком запалення у пацієнта
UY38559A (es)	2019-02-01	2020-07-31	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de la inmunodeficiencia humana
US20220211704A1 (en)	2019-04-30	2022-07-07	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
RU2717101C1 (ru)	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
SI3986561T1 (sl) *	2019-06-19	2024-04-30	VIIV Healthcare UK (No.5) Limited	Pirido(2,3-d)pirimidinski derivati kot zaviralci podvojevanja virusa humane imunske pomanjkljivosti
EP4038068A1 (fr)	2019-10-01	2022-08-10	VIIV Healthcare UK (No.5) Limited	Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2022551256A (ja)	2019-10-01	2022-12-08	ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド	ヒト免疫不全ウイルスの複製阻害剤
TW202128648A (zh)	2019-10-04	2021-08-01	英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司	人類免疫不全病毒複製之抑制劑
WO2021070054A1 (fr)	2019-10-08	2021-04-15	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CN114727999A (zh) *	2019-11-26	2022-07-08	吉利德科学公司	用于预防hiv的衣壳抑制剂
JPWO2021107066A1 (fr)	2019-11-28	2021-06-03
CN114929685B (zh) *	2019-11-29	2023-12-12	江苏恒瑞医药股份有限公司	稠合吡啶环衍生物、其制备方法及其在医药上的应用
CN113304166B (zh) *	2020-02-27	2022-10-14	河南真实生物科技有限公司	核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
BR112022017832A2 (pt)	2020-03-06	2022-11-01	Viiv Healthcare Uk No 5 Ltd	Inibidores de replicação do vírus da imunodeficiência humana
WO2021176367A1 (fr)	2020-03-06	2021-09-10	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202200161A (zh)	2020-03-20	2022-01-01	美商基利科學股份有限公司	4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
CN115397424A (zh)	2020-04-15	2022-11-25	Viiv保健英国第五有限公司	人类免疫缺陷病毒复制的抑制剂
EP4153181A1 (fr)	2020-05-21	2023-03-29	Gilead Sciences, Inc.	Compositions pharmaceutiques contenant du bictégravir
US11680064B2 (en)	2020-06-25	2023-06-20	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of HIV
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
WO2022103758A1 (fr)	2020-11-11	2022-05-19	Gilead Sciences, Inc.	Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120
CA3204255A1 (fr) *	2021-01-25	2022-07-28	Lianhong Xu	Polytherapie contre le vih comprenant un derive d'adenosine et des inhibiteurs de capside
WO2022247942A1 (fr) *	2021-05-28	2022-12-01	江苏恒瑞医药股份有限公司	Sel pharmaceutiquement acceptable et forme cristalline de dérivé cyclique de pyridine fusionné et son procédé de préparation
KR20230019059A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
WO2023102239A1 (fr)	2021-12-03	2023-06-08	Gilead Sciences, Inc.	Composés thérapeutiques contre l'infection par le virus du vih
TW202342447A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
TW202342448A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
TW202400172A (zh)	2022-04-06	2024-01-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (fr) *	2022-07-01	2024-01-04	Gilead Sciences, Inc.	Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
US20240083984A1 (en)	2022-08-26	2024-03-14	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (fr)	2022-10-04	2024-04-11	Gilead Sciences, Inc.	Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
KR20240061218A (ko)	2022-10-31	2024-05-08	주식회사 이보드	복합 단열재 및 제조방법

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja)	1990-06-13	2002-11-20	グラツィエル，アーノルド	含リンプロドラッグ
DE10399025I2 (de)	1990-09-14	2007-11-08	Acad Of Science Czech Republic	Wirkstoffvorläufer von Phosphonaten
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
KR100767432B1 (ko)	2000-07-21	2007-10-17	길리애드 사이언시즈, 인코포레이티드	포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
EP1399420B1 (fr)	2001-06-27	2007-12-05	SmithKline Beecham Corporation	Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
ATE370943T1 (de)	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
DE60218511T2 (de)	2001-10-26	2007-10-25	Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A.	Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (fr)	2003-02-12	2004-08-26	Transtech Pharma Inc.	Derives d'azole substitues comme agents therapeutiques
ATE490788T1 (de)	2003-04-25	2010-12-15	Gilead Sciences Inc	Antivirale phosphonate analoge
EP1939213B1 (fr)	2004-02-27	2010-08-25	Schering Corporation	Nouveaux composés en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en)	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
EP1778251B1 (fr)	2004-07-27	2011-04-13	Gilead Sciences, Inc.	Conjugues de phosphonate nucleosidique comme agents anti-vih
US8067587B2 (en)	2005-07-28	2011-11-29	Lenroc Company	Process for the production of monoalkali metal cyanurates
EP1912989A2 (fr)	2005-08-05	2008-04-23	AstraZeneca AB	Benzimidazoles tricycliques et leur utilisation comme modulateurs du recepteur metabotropique du glutamate
EA014245B1 (ru)	2005-12-14	2010-10-29	Бристол-Маерс Сквибб Компани	Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
CN101466676B (zh)	2006-04-12	2012-07-18	默沙东公司	吡啶基酰胺类t-型钙通道拮抗剂
US7647464B2 (en)	2006-04-28	2010-01-12	At&T Intellectual Property, I,L.P.	Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (fr)	2006-07-27	2008-01-31	E. I. Du Pont De Nemours And Company	Amides azocycliques fongicides
US8124811B2 (en)	2007-03-20	2012-02-28	Allylix, Inc.	Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CN101702908A (zh)	2007-03-23	2010-05-05	麻萨诸塞州大学	Hiv-1蛋白酶抑制剂
US8513186B2 (en)	2007-06-29	2013-08-20	Gilead Sciences, Inc.	Antiviral compounds
EP2175857B1 (fr)	2007-07-12	2013-09-11	Janssen R&D Ireland	Forme cristalline de (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-diméthylphényl]amino]-2-pyrimidinyl]amino]benzonitrile
JP5433573B2 (ja)	2007-07-19	2014-03-05	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	抗ウイルス剤としての大環状化合物
CA2702126A1 (fr)	2007-10-24	2009-04-30	Merck Sharp & Dohme Corp.	Antagonistes des canaux calciques de type t a base d'amide heterocyclique
JP5524071B2 (ja)	2007-10-24	2014-06-18	メルク・シャープ・アンド・ドーム・コーポレーション	複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
CN101918365B (zh)	2007-11-16	2013-10-09	吉联亚科学股份有限公司	人类免疫缺陷病毒复制的抑制剂
JP5537442B2 (ja)	2008-03-13	2014-07-02	ブリストル−マイヤーズスクイブカンパニー	第ｘｉａ因子阻害剤としてのピリダジン誘導体
ES2623794T3 (es)	2008-12-09	2017-07-12	Gilead Sciences, Inc.	Intermedios para la preparación de moduladores de receptores tipo toll
EP2401286A4 (fr)	2009-02-25	2012-09-26	Bigtec Private Ltd	Sondes et amorces pour la détection du chikungunya
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2011094890A1 (fr)	2010-02-02	2011-08-11	Argusina Inc.	Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
WO2011139637A1 (fr)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Modulateurs à petite molécule de stabilité de capside de vih-1 et procédés pour ceux-ci
WO2011143772A1 (fr)	2010-05-21	2011-11-24	Boehringer Ingelheim International Gmbh	Inhibiteurs de la réplication du vih
EP2588455B1 (fr)	2010-07-02	2018-04-04	Gilead Sciences, Inc.	Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv
MA34397B1 (fr)	2010-07-02	2013-07-03	Gilead Sciences Inc	Dérivés d'acide napht-2-ylacétique dans le traitement du sida
CN102464654B (zh)	2010-11-12	2016-01-13	上海泓博智源医药技术有限公司	抗病毒化合物
ME02754B (fr)	2011-03-23	2018-01-20	Trevena Inc	Ligands de récepteurs opïoides, et leurs procédés d'utilisation et de production
UA111841C2 (uk)	2011-04-21	2016-06-24	Гіліад Сайєнсіз, Інк.	Сполуки бензотіазолу та їх фармацевтичне застосування
PT2729448E (pt)	2011-07-06	2015-12-02	Gilead Sciences Inc	Compostos para o tratamento de vih
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
RS55353B2 (sr)	2011-08-16	2023-11-30	Gilead Sciences Inc	Tenofovir alafenamid hemifumarat
US9399645B2 (en)	2011-12-20	2016-07-26	Boehringer Ingelheim International Gmbh	Inhibitors of HIV replication
PE20141558A1 (es)	2012-04-20	2014-11-06	Gilead Sciences Inc	Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
GB201213087D0 (en)	2012-07-24	2012-09-05	Medical Res Council	Inhibition of HIV-1 infection
US9447134B2 (en)	2012-08-17	2016-09-20	Brandeis University	Compounds and methods for treating mammalian gastrointestinal microbial infections
DK3067358T3 (da)	2012-12-21	2019-11-04	Gilead Sciences Inc	Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
EP2940019B1 (fr)	2012-12-27	2018-03-28	Japan Tobacco Inc.	DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET SON UTILISATION MÉDICALE EN TANT QU'INHIBITEUR D'INTÉGRASE DU VIH
ES2642265T3 (es)	2013-01-09	2017-11-16	Gilead Sciences, Inc.	Compuestos terapéuticos para el tratamiento de infecciones virales
AU2014205317B2 (en)	2013-01-09	2016-11-24	Gilead Sciences, Inc.	5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh)	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
EP2769722A1 (fr)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Composés utilisés pour inhiber un assemblage de capside du VIH
TWI694071B (zh) *	2013-03-01	2020-05-21	美商基利科學股份有限公司	治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en)	2013-03-01	2014-10-02	Gilead Sciences, Inc.	Therapeutic compounds
GB201312991D0 (en)	2013-07-19	2013-09-04	Isis Innovation	Process
MX2016004492A (es)	2013-10-24	2016-06-16	Squibb Bristol Myers Co	Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
WO2015130966A1 (fr)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Agents antiviraux
US10202353B2 (en)	2014-02-28	2019-02-12	Gilead Sciences, Inc.	Therapeutic compounds
WO2016033243A1 (fr) *	2014-08-29	2016-03-03	Gilead Sciences, Inc.	Agents antirétroviraux
WO2016040084A1 (fr)	2014-09-09	2016-03-17	Bristol-Myers Squibb Company	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
MX2017008520A (es)	2014-12-24	2018-03-01	Gilead Sciences Inc	Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
TWI770552B (zh)	2014-12-24	2022-07-11	美商基利科學股份有限公司	喹唑啉化合物
BR112017022605A2 (pt)	2015-04-23	2018-07-17	Viiv Healthcare Uk No 5 Ltd	?composto, composição, e, método para tratamento de infecção por hiv?.
CN107995910A (zh)	2015-04-23	2018-05-04	Viiv保健英国第五有限公司	人免疫缺陷病毒复制的抑制剂
CA2971640C (fr) *	2015-07-06	2020-09-22	Gilead Sciences, Inc.	Modulateurs de cot et procedes d'utilisation associes
US10171985B1 (en)	2015-07-22	2019-01-01	Ginko LLC	Method and apparatus for data sharing
CN109890808B (zh)	2016-08-19	2020-08-07	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
TW201906834A (zh)	2017-05-02	2019-02-16	英商Viiv醫療保健英國(No.5)有限公司	人類免疫不全病毒複製之抑制劑
TWI687415B (zh)	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
JP7083398B2 (ja)	2018-02-15	2022-06-10	ギリアードサイエンシーズ，インコーポレイテッド	ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
CA3175384A1 (fr)	2018-02-16	2019-08-22	Gilead Sciences, Inc.	Methodes et intermediaires pour preparer des composes therapeutiques utiles dans le traitement d'une infection virale des retroviridae
US10911396B2 (en)	2018-06-28	2021-02-02	Paypal, Inc.	Mid-tier messaging system
KR20210033492A (ko)	2018-07-16	2021-03-26	길리애드 사이언시즈, 인코포레이티드	Hiv의 치료를 위한 캡시드 억제제
CN114727999A (zh)	2019-11-26	2022-07-08	吉利德科学公司	用于预防hiv的衣壳抑制剂
US11680064B2 (en)	2020-06-25	2023-06-20	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of HIV

2017
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active IP Right Grant
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/fr active Application Filing
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Application Discontinuation
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
- 2017-08-17 TW TW112100805A patent/TW202342449A/zh unknown
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Application Discontinuation
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 CA CA3021227A patent/CA3021227C/fr active Active
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/fr active Pending
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 CN CN202010662665.4A patent/CN111793061A/zh active Pending
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/fr active Active
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/fr active Active
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-13 HK HK18116015.7A patent/HK1256904B/zh unknown
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja active Pending
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
2023
- 2023-01-05 LT LTPA2023501C patent/LTPA2023501I1/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739A1/en active Pending

Also Published As

Publication number	Publication date
EP3347352A1 (fr)	2018-07-18
DOP2019000033A (es)	2019-03-15
CO2019001379A2 (es)	2019-02-19
HUE045137T2 (hu)	2019-12-30
ES2746374T3 (es)	2020-03-05
PL3597646T3 (pl)	2023-12-11
CY1122296T1 (el)	2021-01-27
AU2017312102A1 (en)	2019-03-07
JP6716785B2 (ja)	2020-07-01
HRP20231018T1 (hr)	2023-12-08
ECSP19011209A (es)	2019-02-28
JP2020111592A (ja)	2020-07-27
HK1256904B (zh)	2020-07-17
US11993583B2 (en)	2024-05-28
MA42795B1 (fr)	2019-08-30
DK3347352T3 (da)	2019-08-26
SG11201808944QA (en)	2018-11-29
UY37367A (es)	2018-03-23
TWI715944B (zh)	2021-01-11
FI3597646T3 (fi)	2023-09-07
TW201922711A (zh)	2019-06-16
BR112018071678B1 (pt)	2021-01-26
PT3347352T (pt)	2019-09-24
EP3597646A1 (fr)	2020-01-22
AU2021221855A1 (en)	2021-09-23
PH12019500335A1 (en)	2019-11-11
FR22C1063I2 (fr)	2023-12-15
SA519401123B1 (ar)	2022-11-09
MY191466A (en)	2022-06-28
MA42795A (fr)	2019-07-03
CA3021227A1 (fr)	2018-02-22
EP4265299A3 (fr)	2024-01-17
LTPA2023501I1 (fr)	2023-02-10
AU2023271739A1 (en)	2023-12-14
TW202342449A (zh)	2023-11-01
LT3347352T (lt)	2019-08-12
HUS2200053I1 (hu)	2023-01-28
MX369307B (es)	2019-11-05
KR20200131351A (ko)	2020-11-23
JP2021008516A (ja)	2021-01-28
PT3597646T (pt)	2023-09-11
JOP20180123A1 (ar)	2019-01-30
PL3347352T3 (pl)	2019-12-31
NL301212I1 (fr)	2023-01-12
AU2021221855B2 (en)	2023-08-31
BR122020001791B1 (pt)	2022-01-25
HUE063811T2 (hu)	2024-02-28
US20200262815A1 (en)	2020-08-20
CN111793061A (zh)	2020-10-20
CL2019000415A1 (es)	2019-06-21
EP3597646B1 (fr)	2023-06-21
SI3347352T1 (sl)	2019-08-30
BR112018071678A2 (pt)	2019-02-19
NL301212I2 (nl)	2023-04-06
KR102180740B1 (ko)	2020-11-20
AU2017312102B2 (en)	2020-03-05
FR22C1063I1 (fr)	2023-02-03
LT3597646T (lt)	2023-09-25
AU2020202331B2 (en)	2021-05-27
CN109890808B (zh)	2020-08-07
EP4265299A2 (fr)	2023-10-25
TW201811327A (zh)	2018-04-01
ZA201901430B (en)	2021-09-29
AU2020202331C1 (en)	2021-08-26
ES2954514T3 (es)	2023-11-22
US20180051005A1 (en)	2018-02-22
TW202138365A (zh)	2021-10-16
MX2018012905A (es)	2019-01-30
US10071985B2 (en)	2018-09-11
KR20190039431A (ko)	2019-04-11
CN109890808A (zh)	2019-06-14
TWI664966B (zh)	2019-07-11
NZ750706A (en)	2020-07-31
PE20211427A1 (es)	2021-08-03
US10654827B2 (en)	2020-05-19
JP2019528280A (ja)	2019-10-10
DK3597646T3 (da)	2023-09-04
AU2020202331A1 (en)	2020-04-23
EP3347352B1 (fr)	2019-07-03
IL264644B (en)	2019-09-26
WO2018035359A1 (fr)	2018-02-22
SI3597646T1 (sl)	2023-10-30
CR20190084A (es)	2019-05-02
SG10201912535VA (en)	2020-02-27
PE20190910A1 (es)	2019-06-26
JP2023011754A (ja)	2023-01-24
KR20230011471A (ko)	2023-01-20
US20180370950A1 (en)	2018-12-27
CA3021227C (fr)	2020-11-03

Publication	Publication Date	Title
FR22C1063I2 (fr)	2023-12-15	Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA45539A (fr)	2019-05-08	Dihydropyranopyrimidines pour le traitement d'infections virales
MA44083A (fr)	2021-06-02	Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA50482A (fr)	2020-09-02	Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA45052A (fr)	2019-03-27	Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
MA40867A (fr)	2017-09-06	Méthodes pour le traitement d'infections virales à filoviridae
MA55629A (fr)	2022-05-04	Compositions d'anticorps pour le traitement de tumeurs
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
MA43811A (fr)	2018-11-28	Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA54925A (fr)	2021-12-22	Compositions pour le traitement de troubles acido-basiques
CA3010327A1 (fr)	2017-07-27	Pyrimidines a substitution aryle a utiliser dans une infection par le virus de la grippe
MA55720A (fr)	2022-02-23	Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
MA45999A (fr)	2019-06-26	Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA43314A (fr)	2018-10-03	Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques
MA51738A (fr)	2021-05-12	Composés pour le traitement de la douleur
MA49576A (fr)	2021-04-07	Compositions et méthodes pour le traitement d'infections fongiques
MA45552A (fr)	2019-05-08	Compositions destinées au traitement de l'amylose
MA45226A (fr)	2019-04-17	Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA51613A (fr)	2020-11-25	Polythérapie pour le traitement ou la prévention du cancer
MA54522A (fr)	2022-03-23	Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA46967A (fr)	2019-10-09	Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA45227A (fr)	2019-04-17	Peptides pour le traitement de l'ostéoarthrite
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression
MA43812A (fr)	2018-11-28	Procédés et compositions pour le traitement d'une infection par le virus zika
FR3057455B1 (fr)	2018-11-02	Equipement pour le traitement d'une fracture par haubanage, par exemple d'une fracture de l'olecrane ou de la rotule